MarketInOut Stock Screener Log In | Sign Up
 

Novavax Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Novavax Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,611.52 mln
Float157 mln
Earnings Date11/05/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-4.83
Highly reliable

1-Year Forecast

14.22
Exceptional upside

Relative Strength

9 / 100
Severely lagging

Pre-Tax Margin

-59%
Severely loss-making

ROE

160
Extraordinary

Business Description

Founded in 1987 and based in Gaithersburg, Maryland, Novavax works to protect people from serious infectious diseases by bringing new vaccines to market across the United States, Europe, and beyond. Its current products include a COVID-19 vaccine and a malaria vaccine, both of which it develops and sells through partnerships with major pharmaceutical companies such as Sanofi, Pfizer, Takeda, and Serum Life Sciences.

Key Fundamentals

EPS-1.58
ROE160
RPS2.54
ROIC-23.06
ROA-21.74
Interest Cover-18.80
EBITDA, mln-206
EV / EBITDA-6.61
EV / EBIT-6.08
Revenue, mln414
EV / Revenue3.28

Quote Details

Last 9.70
Change -0.29 (-2.9%)
Open 9.84
Volume 4,412,237
Turnover 42,798,700
Average Volume 8,694,933

Financial Ratios

Pre-Tax Profit Margin-59
Current Ratio2.33
Price / Sales4.28
PEG Ratio1.32

Financial Strength

Altman Z-Score-5.64
Piotroski F-Score 2 / 9
Beneish M-Score-4.83
1-Year Target Price14.22
Short Ratio8.08
Short % of Float28.10

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -13.85% 6 / 100   
1 Month -8.49% 32 / 100   
2 Months 23.1% 93 / 100   
6 Months 18% 88 / 100   
1 Year 14.66% 73 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog